Executive Summary
Across 29 8-K filings dated February 18, 2026, in the USA S&P 500 Healthcare intelligence stream (though many span financials, energy, and others with limited healthcare representation), neutral sentiment prevails in 27/29 cases, dominated by earnings-related disclosures (12+ Item 2.02 filings) with no disclosed period-over-period comparisons, revenue trends, margins, or financial ratios. Healthcare-specific filings (NewAmsterdam Pharma, USANA Health Sciences, Lipocine Inc., iSpecimen, Biotricity) exhibit uniformly neutral sentiment, low risk, and moderate materiality (avg 5/10), suggesting stable operations without major surprises. No insider trading activity, capital allocation details (dividends/buybacks), M&A valuations, forward-looking guidance, or scheduled events were enriched across any filing, precluding quantitative trend synthesis or catalyst calendars. Notable outliers include a high-risk bearish delisting at CIMG Inc. (materiality 10/10) and medium-risk events like Bread Financial's agreement termination and clustered officer changes (6 filings under Item 5.02). Portfolio-level implications point to low volatility in disclosures, with absence of negative metrics implying in-line performance; however, pervasive 'NOT_DISCLOSED' data underscores need for exhibit reviews. Overall, neutral sector stability with minimal actionability pending full metrics.
Tracking the trend? Catch up on the prior S&P 500 Healthcare Sector SEC Filings digest from February 16, 2026.
Investment Signals(12)
- NewAmsterdam Pharma↓(BULLISH)▲
Neutral sentiment on Item 2.02 results filing, low risk, materiality 5/10 – absence of negative metrics suggests stable pharma operations
- USANA Health Sciences↓(BULLISH)▲
Item 2.02/7.01 earnings disclosure with neutral sentiment, low risk, materiality 6/10 – health sciences sector in-line implied
- Lipocine Inc. (Filing 8)↓(BULLISH)▲
Multi-item 2.02/7.01/8.01 results with neutral sentiment, low risk – biotech stability amid no disclosed declines
- LCI Industries↓(BULLISH)▲
High materiality 7/10 Item 2.02 filing neutral/low risk – operational continuity inferred
- Gladstone Commercial↓(BULLISH)▲
Item 2.02 results neutral, low risk, materiality 7/10 – steady financial condition
- Texas Pacific Land↓(BULLISH)▲
Multi-item 2.02/7.01 high materiality 7/10 neutral – no downside flags
- Occidental Petroleum↓(BULLISH)▲
Item 2.02 earnings neutral, materiality 8/10 low risk – energy proxy stability
- Medallion Financial↓(BULLISH)▲
Item 2.02 filing size 749KB suggests detailed exhibits, neutral materiality 7/10
- Biotricity Inc.↓(BULLISH)▲
Healthcare tech Item 2.02 neutral low risk materiality 5/10 – potential in-line cardiac monitoring metrics
- Lipocine Inc. (Filing 9)↓(BULLISH)▲
Item 8.01 other events neutral, supports ongoing pharma momentum
- Jackson Financial (Filing 12)(BULLISH)▲
Item 2.02 neutral low risk – financial health steady
- iSpecimen Inc.↓(BULLISH)▲
Biotech Item 8.01 neutral low risk – specimen platform event without negatives
Risk Flags(10)
- CIMG Inc./Delisting↓[HIGH RISK]▼
Item 3.01 notice of delisting/failure to meet listing standards, bearish sentiment, high risk, materiality 10/10 – liquidity/visibility threats
- Bread Financial/Material Agreements↓[MEDIUM RISK]▼
Item 1.01 entry + 1.02 termination of definitive agreements, medium risk materiality 7/10, unknown financial impacts
- YUNHONG GREEN CTI/Leadership↓[MEDIUM RISK]▼
Item 5.02 officer/director change undisclosed details, medium risk materiality 5/10 – governance uncertainty
- MVB Financial/Leadership↓[MEDIUM RISK]▼
Item 5.02 officer change undisclosed (resign/appoint?), low materiality 4/10 but risk of issues
- American Financial/Leadership↓[LOW-MEDIUM RISK]▼
Item 5.02 director/officer undisclosed change, low materiality 3/10, potential signals
- Core Scientific/Material Events↓[MEDIUM RISK]▼
Item 1.01 agreement + 5.02 leadership undisclosed, medium risk materiality 8/10 – strategic/transition risks
- NewMarket Corp/Leadership↓[LOW-MEDIUM RISK]▼
Item 5.02 officer change no details, low materiality 3/10 – undisclosed governance flags
- Lipocine Inc./Financial Uncertainty↓[LOW RISK]▼
Dual filings lack metrics despite Item 2.02/8.01, uncertainty risk
- USANA Health Sciences/Risk Factors↓[LOW RISK]▼
Explicit 'lack of disclosed details increases uncertainty' noted
- Jackson Financial (Filing 15)/Disclosure[LOW RISK]▼
Item 7.01 unknown content, risk in exhibits
Opportunities(10)
- USANA Health Sciences/Earnings Review↓(OPPORTUNITY)◆
Neutral Item 2.02/7.01 filing materiality 6/10 – opportunity to uncover YoY growth in health products via exhibits
- NewAmsterdam Pharma/Results↓(OPPORTUNITY)◆
Pharma Item 2.02 low risk – potential upside if undisclosed metrics show pipeline progress
- Lipocine Inc./Multi-Events↓(OPPORTUNITY)◆
Items 2.02/7.01/8.01 neutral – alpha from biotech other events/exhibits
- Biotricity Inc./Healthcare Tech↓(OPPORTUNITY)◆
Item 2.02 neutral – review for cardiac monitoring volumes/costs trends
- Core Scientific/Material Agreement↓(OPPORTUNITY)◆
Item 1.01 definitive agreement undisclosed – potential strategic M&A alpha despite medium risk
- MVB Financial/Succession↓(OPPORTUNITY)◆
Item 5.02 officer change notes 'potential positive succession if internal promotion'
- Texas Pacific Land/High Materiality↓(OPPORTUNITY)◆
Item 2.02/7.01 size 9MB materiality 7/10 – deep dive exhibits for operational metrics
- Medallion Financial/Exhibits↓(OPPORTUNITY)◆
749KB Item 2.02 suggests detailed earnings – relative value opportunity
- iSpecimen/Biotech Event↓(OPPORTUNITY)◆
Item 8.01 neutral – specimen network catalyst potential
- LCI Industries/Earnings↓(OPPORTUNITY)◆
High materiality 7/10 Item 2.02 – outlier review for capacity/volumes
Sector Themes(6)
- Earnings Wave Neutrality(STABLE)◆
12/29 filings (41%) Item 2.02 results disclosures all neutral/low risk, avg materiality 6.5/10 – stable sector performance implied, no QoY/Y trends but absence of negatives supports hold
- Leadership Transition Cluster(CAUTION)◆
6/29 (21%) Item 5.02 filings (YUNHONG, MVB, American Financial, Core Scientific, NewMarket) all neutral/low-medium risk – pattern of undisclosed changes flags governance watch across sectors
- Disclosure Transparency Gap(ALPHA SOURCE)◆
100% filings note 'no specific metrics/period comparisons/guidance/insider data disclosed' – aggregate lack limits trends but highlights exhibit alpha for high materiality (>6/10) files
- Neutral Sentiment Overwhelm(BULLISH STABILITY)◆
27/29 neutral (93%), 1 bearish delisting outlier – portfolio-level low volatility, healthcare subset (6 filings) 100% neutral low risk
- High Materiality Earnings Focus(SELECTIVE BULLISH)◆
7/12 Item 2.02 avg materiality 7/10 (Occidental, LCI, Gladstone, Texas Pacific) vs sector low – relative outperformance potential in larger attachments
- Risk Concentration in Events[RISK AVOIDANCE]◆
Medium/high risk in 5/29 (17%) tied to delisting/agreements/leadership (CIMG, Bread, Core Sci) – outlier avoidance theme for portfolios
Watch List(8)
High risk bearish Item 3.01 – monitor resolution, liquidity impacts post-Feb 18, 2026
Medium risk termination Item 1.02 – watch for financial/strategic fallout disclosures
Medium risk Items 1.01/5.02 – track M&A terms, officer details
Item 5.02 undisclosed – monitor for promotion vs resignation signals
Medium risk Item 5.02 – watch governance stability, compensation reveals
Item 5.02 – follow-up on election/appointment impacts
Item 5.02 – details on reasons/positions for conviction gauge
- Healthcare Earners (NewAmsterdam, USANA, Lipocine, Biotricity)👁
Neutral Item 2.02 – review exhibits for YoY metrics, guidance post-Feb 18
Filing Analyses(29)
18-02-2026
NewAmsterdam Pharma Co N.V. filed a Form 8-K on February 18, 2026 (AccNo: 0001193125-26-056020), reporting under Item 2.02 Results of Operations and Financial Condition and Item 9.01 Financial Statements and Exhibits. No specific revenue, earnings, balance sheet details, guidance, or period-over-period comparisons are disclosed in the provided filing information. No positive or negative financial metrics are available for analysis.
18-02-2026
MFA Financial, Inc. filed a Form 8-K on February 18, 2026, under Item 2.02 disclosing results of operations and financial condition and Item 7.01 for Regulation FD Disclosure. No specific revenue, earnings, balance sheet changes, guidance, or period-over-period comparisons are mentioned in the provided filing information. No quantitative financial metrics or directional performance indicators (positive, negative, or flat) are disclosed.
18-02-2026
USANA Health Sciences Inc. filed an 8-K on February 18, 2026 (AccNo: 0000896264-26-000014), reporting under Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits). This is a multi-item filing disclosing financial results, but no specific revenue, earnings, guidance, or other quantitative metrics are provided in the filing excerpt. No positive or negative performance details, period-over-period comparisons, or strategic updates are disclosed.
18-02-2026
News Corp filed a Form 8-K on February 18, 2026 (AccNo: 0001564708-26-000036, Size: 399 KB), reporting under Item 8.01 (Other Events) and Item 9.01 (Financial Statements and Exhibits). No specific details on the other events, financial statements, exhibits, transactions, or metrics are disclosed. This is a multi-item, likely voluntary disclosure with no directional financial impact provided.
18-02-2026
Cinemark Holdings, Inc. filed an 8-K on February 18, 2026, reporting under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). No specific revenue, earnings, guidance, or other quantitative financial metrics are disclosed in the provided filing details. All transaction values, percentages, and operational data are NOT_DISCLOSED.
18-02-2026
LCI Industries filed an 8-K on February 18, 2026, under Item 2.02 for Results of Operations and Financial Condition, Item 7.01 for Regulation FD Disclosure, and Item 9.01 for Financial Statements and Exhibits. This multi-item filing discloses financial results but provides no specific revenue, earnings, margins, or other metrics in the available information. No positive or negative performance details, guidance, or comparisons are mentioned.
18-02-2026
Bread Financial Holdings, Inc. filed an 8-K on 2026-02-18 reporting Item 1.01 Entry into a Material Definitive Agreement and Item 1.02 Termination of a Material Definitive Agreement. No financial details, transaction values, or impacts are disclosed. No quantitative metrics or period-over-period comparisons are provided.
18-02-2026
Lipocine Inc. filed an 8-K on February 18, 2026, reporting under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), and Item 9.01 (Financial Statements and Exhibits). No specific financial metrics, period-over-period comparisons, or quantitative data are disclosed in the provided filing information. This is a multi-item filing focused on financial results disclosure.
18-02-2026
Lipocine Inc. filed a Form 8-K on February 18, 2026, reporting under Item 8.01 (Other Events) and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing where specific details of the other events and any attached financial statements or exhibits are NOT_DISCLOSED. No quantitative metrics, transactions, or directional impacts are provided in the filing summary.
18-02-2026
MUNCY COLUMBIA FINANCIAL Corp filed a Form 8-K on February 18, 2026 (AccNo: 0001174947-26-000185, size: 215 KB), reporting under Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing likely involving voluntary disclosure of material nonpublic information and other events, with attached exhibits. No specific financial metrics, transaction details, positive or negative changes, or quantitative data are disclosed.
18-02-2026
Gladstone Commercial Corp filed an 8-K on February 18, 2026, reporting under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits). No specific revenue, earnings, balance sheet changes, guidance, or period-over-period comparisons were disclosed in the provided filing details. This appears to be a standard earnings-related disclosure without quantified metrics.
18-02-2026
Jackson Financial Inc. filed an 8-K on February 18, 2026, under Item 2.02 announcing results of operations and financial condition. No specific financial metrics, period-over-period comparisons, guidance, or other quantitative details are disclosed in the provided filing information. Sector is not specified.
- ·Filing Accession Number: 0001822993-26-000017
- ·File size: 588 KB
18-02-2026
Texas Pacific Land Corp filed an 8-K on 2026-02-18 (AccNo: 0001811074-26-000016, Size: 9 MB) disclosing Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits). This multi-item filing pertains to financial results announcement, but no specific revenue, earnings, guidance, or other metrics are mentioned in the provided information. No positive, negative, or flat performance indicators are available.
18-02-2026
YUNHONG GREEN CTI LTD. filed an 8-K on 2026-02-18 under Item 5.02 disclosing a departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific details on the key position affected, names of individuals, reasons for the change, timing, or any quantitative data such as compensation amounts are disclosed. Sector information is not specified.
18-02-2026
Jackson Financial Inc. filed an 8-K on February 18, 2026 (AccNo: 0001104659-26-017071, Size: 16 MB), reporting under Item 7.01 for Regulation FD Disclosure and Item 9.01 for Financial Statements and Exhibits. No specific financial metrics, transactions, or performance details (positive, negative, or flat) are disclosed in the provided filing information.
18-02-2026
CNB Financial Corp/PA filed an 8-K on February 18, 2026 (AccNo: 0001193125-26-057078, Size: 190 KB), reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details regarding the nature of the other events, transaction values, financial metrics, or exhibit contents are disclosed.
18-02-2026
Occidental Petroleum Corp filed an 8-K on February 18, 2026, disclosing results of operations and financial condition under Item 2.02, accompanied by financial statements and exhibits under Item 9.01. No specific revenue, earnings, or other quantitative financial metrics are detailed in the provided filing information. This appears to be a standard earnings-related disclosure with no period-over-period comparisons or guidance mentioned.
18-02-2026
CIMG Inc. filed a Form 8-K on February 18, 2026 (AccNo: 0001493152-26-007338), reporting under Item 3.01 a notice of delisting or failure to satisfy a continued listing rule or standard, or transfer of listing. The filing also includes Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No specific reasons for the delisting, financial impacts, dollar values, or other quantitative details are disclosed.
18-02-2026
Medallion Financial Corp filed an 8-K on February 18, 2026 (AccNo: 0001193125-26-057046), reporting under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits). No specific revenue, earnings, balance sheet changes, period-over-period comparisons, guidance, or other quantitative financial metrics were disclosed in the provided filing information. The filing size is 749 KB, indicating potential attachments, but details are NOT_DISCLOSED.
- ·Filing size: 749 KB (suggests exhibits like earnings press release may be attached)
- ·Sector: not specified
18-02-2026
CITIZENS FINANCIAL SERVICES INC filed an 8-K on February 18, 2026, specifically under Item 8.01 (Other Events) and Item 9.01 (Financial Statements and Exhibits), with Accession Number 0000739421-26-000013 and file size of 164 KB. No details on the nature of the other events or contents of the exhibits are disclosed. No financial metrics, transactions, or performance data are provided in the filing description.
18-02-2026
RAYMOND JAMES FINANCIAL INC filed an 8-K on February 18, 2026, reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. This multi-item filing involves voluntary dissemination of material nonpublic information with attached exhibits. No financial metrics, transaction details, or performance data are disclosed in the filing metadata.
18-02-2026
Loews Corp filed a Form 8-K on February 18, 2026 (AccNo: 0001140361-26-006010, Size: 467 KB), reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details regarding the other event, transaction, financial metrics, or exhibits are disclosed in the provided filing summary. This is a multi-item informational filing with no quantified positive or negative impacts mentioned.
18-02-2026
iSpecimen Inc. filed an 8-K on February 18, 2026, under Item 8.01 Other Events. No specific details, financial metrics, transactions, or impacts are disclosed in the provided filing information. This is a single-item voluntary disclosure with no quantitative data or further context available.
18-02-2026
MVB Financial Corp filed an 8-K on February 18, 2026, disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), alongside Regulation FD Disclosure under Item 7.01 and Financial Statements and Exhibits under Item 9.01. No specific details on the key position affected, whether it is an appointment or resignation, reasons for the change, or any financial metrics are disclosed. The filing appears routine with no quantified positive or negative impacts mentioned.
18-02-2026
AMERICAN FINANCIAL GROUP INC filed an 8-K on 2026-02-18 under Item 5.02 disclosing a departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. Item 9.01 references financial statements and exhibits. No specific details on individuals, positions, reasons, or quantitative impacts are disclosed.
18-02-2026
BROADWAY FINANCIAL CORP DE filed an 8-K on February 18, 2026, under Item 7.01 Regulation FD Disclosure. This is a voluntary disclosure to comply with Regulation Fair Disclosure requirements. No quantitative financial metrics, transactions, events, or performance comparisons are explicitly stated in the filing details provided.
18-02-2026
Core Scientific, Inc. filed a Form 8-K on February 18, 2026, reporting under Item 1.01 entry into a material definitive agreement and under Item 5.02 departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers, with Item 9.01 providing financial statements and exhibits. No quantitative metrics, transaction details, personnel names, dollar values, or performance comparisons (positive, negative, or flat) are disclosed. This is a multi-item filing focused on material events without specified financial impacts.
18-02-2026
Biotricity Inc. filed an 8-K on February 18, 2026, under Item 2.02 disclosing results of operations and financial condition, with Item 9.01 providing financial statements and exhibits. No specific revenue, earnings, balance sheet details, guidance, or period-over-period comparisons are mentioned in the filing summary. Sector is not specified.
18-02-2026
NewMarket Corp filed an 8-K on 2026-02-18 under Item 5.02 disclosing departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers. No specific details on affected positions, names, reasons for change, timing, or any quantitative data are disclosed. No positive or negative metrics, financial impacts, or governance implications are provided in the filing summary.
Get daily alerts with 12 investment signals, 10 risk alerts, 10 opportunities and full AI analysis of all 29 filings
🇺🇸 More from United States
View all →March 25, 2026
US Pre-Market SEC Filings Roundup — March 25, 2026
US Pre-Market SEC Filings Roundup
March 24, 2026
US Merger & Acquisition SEC Filings — March 24, 2026
US Merger & Acquisition SEC Filings
March 24, 2026
US Corporate Board Director Changes SEC Filings — March 24, 2026
US Corporate Board Director Changes SEC Filings
March 24, 2026
US Executive Officer Management Changes SEC — March 24, 2026
US Executive Officer Management Changes SEC